Clinical Trials on Influenza, Human

Total 8080 results

MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
National Institute of Allergy and Infectious Diseases...

Completed

Age and Response to Flu Vaccines

Influenza | Influenza Immunisation

United States
Ology Bioservices

Completed

Yearly Strain Variation Study, 2010/2011

Influenza | Seasonal Influenza

Austria
National Institute of Allergy and Infectious Diseases...

Completed

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Influenza | Influenza Immunisation

United States
GlaxoSmithKline

Completed

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Influenza | Influenza Vaccines

Taiwan, Hong Kong, Thailand, Singapore
Celltrion

Completed

A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model

Influenza A

United Kingdom
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Qingdao Municipal Hospital; Beijing Luhe Hospital; Cangzhou People's Hospital; First... and other collaborators

Unknown

Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms

Severe Influenza

China
University of Warwick
University Hospital Birmingham

Completed

An Improvement Project Around Staffs' Influenza Vaccine Uptake

Influenza Vaccination

United Kingdom
Advagene Biopharma Co. Ltd.

Completed

A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult

Influenza Infection

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
Duke University
United States Department of Defense; Imperial College of London

Unknown

Biomarkers Predicting Infectivity in an Experimental Human Influenza Model (PRESAGE)

Influenza A

United Kingdom
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Influenza | Seasonal Influenza

United Kingdom
Immune Targeting Systems Ltd

Completed

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

Influenza A

United Kingdom
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Seasonal Influenza

Italy
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Ology Bioservices

Completed

Yearly Strain Variation Study, 2009/2010

Influenza | Seasonal Influenza

Austria
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
University of British Columbia
PHAC/CIHR Influenza Research Network

Completed

Comparison of 4 Influenza Vaccines in Seniors (PCIRNRT09)

Influenza Vaccine

Canada
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Columbia University

Completed

Adult Influenza Vaccination Text Message Reminders

Influenza Vaccination

United States
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Influenza (Pandemic)

United States
Novavax

Completed

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Pandemic Influenza

United States
St. Jude Children's Research Hospital

Completed

Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults

Influenza Virus

United States
International Centre for Infectious Diseases, Canada
GlaxoSmithKline

Unknown

H1N1 Vaccine Safety in Manitoba, Canada

H1N1 Influenza

Canada
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B (PIPET B)

Pandemic Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza (PIPET C)

Pandemic Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

Seasonal Influenza

Germany
Abbott Biologicals
Quintiles, Inc.

Completed

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

Influenza Vaccines

Czech Republic, Estonia, Lithuania
Dalhousie University
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR); IWK Health Centre

Completed

Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Seasonal Influenza

Canada
The University of Hong Kong

Completed

Convalescent Plasma Treatment in Severe 2009 H1N1 Infection

Influenza A

China
Seoul National University Hospital

Unknown

The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A

H1N1 Influenza

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Orakine Ltd, Dublin, Ireland

Terminated

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer (GP-INFA)

Influenza Infection

France
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.

Influenza Disease

Italy
Biomedical Advanced Research and Development Authority
PPD

Completed

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

A/Vietnam/H5N1 Influenza Virus

United States
Institute of Vaccines and Medical Biologicals,...
Department of Health and Human Services; Institut Pasteur; PATH; World Health Organization

Completed

Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Influenza A Subtype H5N1 Infection

Vietnam
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Influenza A Virus, H5N1 Subtype

United States
National Institute of Allergy and Infectious Diseases...
University of Rochester

Completed

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

Influenza A Virus, H7N9 Subtype

United States
St. Jude Children's Research Hospital
National Institute of Allergy and Infectious Diseases (NIAID); The University...

Completed

Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China

Influenza Type B | Influenza Type A

China
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Avian Influenza | Immunisation

United States
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
University of California, Los Angeles
University of Rochester; Agency for Healthcare Research and Quality (AHRQ)

Completed

School-located Influenza Vaccination Clinics for Adolescents (SKIPP RCT2)

Childhood Influenza Vaccination | School-located Influenza Vaccination
University of California, Los Angeles

Completed

Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York (SKIPP RCT)

Childhood Influenza Vaccination | School-located Influenza Vaccination

United States
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Influenza A Virus, H7N9 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Influenza A Virus, H7N9 Subtype

United States
University of Witwatersrand, South Africa

Completed

Influenza Vaccine in HIV Infected Children

Influenza With Pneumonia, Influenza Virus Identified

South Africa
GlaxoSmithKline

Completed

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

Haemophilus Influenzae | Streptococcus Pneumoniae

Sweden
GlaxoSmithKline

Terminated

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

Haemophilus Influenzae | Streptococcus Pneumoniae

Canada

Clinical Trials on Influenza, Human

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations